In this article, we will take a look at the 10 Fast-Growing AI Healthcare Companies to Watch Right Now. In this piece, we take a closer look at Oscar Health Inc. (NYSE:OSCR) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.
Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.
Why Medicine Could Be AI’s Next Major Market
Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.
Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.
These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.
A Low Share Price Does Not Always Mean Cheap
A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.
The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.
Finding the Best AI Medicine Stocks
This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.
The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.
CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.
Our Methodology
For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.
10 Best Cheap AI Medicine Stocks to Buy Now
6. Oscar Health Inc. (NYSE:OSCR)
Oscar Health, Inc. (NYSE: OSCR) occupies sixth place as a technology-driven health insurer using data, automation and artificial intelligence to improve member services and control administrative costs.
The company participates primarily in the Affordable Care Act insurance market. Its digital platform helps members understand their coverage, navigate the healthcare system and connect with appropriate services.
Behind the consumer interface, the company uses technology to support claims processing, care management, member communication and medical-cost analysis. Its +Oscar platform can also provide technology services to other organizations in the healthcare industry.
Second-quarter 2026 revenue increased approximately 70% to $4.88 billion. Earnings reached $1.10 per share, reversing a loss of $0.89 per share in the comparable period and comfortably exceeding market expectations.
The company also raised its full-year earnings forecast to between $500 million and $700 million while maintaining annual revenue guidance of approximately $18.7 billion to $19 billion.
Those numbers make it one of the largest and fastest-growing companies on the list. Its improving medical loss ratio also suggests that the business is becoming more effective at managing healthcare expenses.
Oscar Health, Inc. (NYSE: OSCR) does not rank higher because it remains an insurance company first and an AI company second. Its financial performance can be affected by government policy, premium subsidies, risk-adjustment payments and changes in the health of its membership base.
The expiration or reduction of enhanced Affordable Care Act subsidies could cause some customers to leave the market. A decline in younger and healthier members could also make the remaining insurance pool more expensive to serve.
The company nevertheless deserves a place among AI healthcare companies to watch. It has demonstrated that a digitally designed insurer can gain market share and improve profitability. The next challenge is proving that its technology can continue delivering better operating results under less favorable policy conditions.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
